

Please type a plus sign (+) inside this box →

Approved for use through 09/30/2000. OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. TSRI 433.1 Div 1

First Inventor or Application Identifier Sherman

Title IN VIVO ACTIVATION OF TUMOR SPECIFIC...

Express Mail Label No. EL193838790US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2.  Specification [Total Pages 130]  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3.  Drawing(s) (35 U.S.C. 113) [Total Sheets 22]
4. Oath or Declaration [Total Pages ]  
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 17 completed)  
*[Note Box 5 below]*
    - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).
5.  Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment

Continuation  Divisional  Continuation-in-part (CIP) of prior application No: 08 / 860,232

Prior application information: Examiner Y. Eyer Group / Art Unit: 1642

## 18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label  
(Insert Customer No. or Attach bar code label here) or  Correspondence address below

Name	THOMAS E. NORTHRUP				
	THE SCRIPPS RESEARCH INSTITUTE				
Address	10550 North Torrey Pines Road,				
	Mail Drop: TPC-8				
City	La Jolla	State	CA	Zip Code	92037
Country	US	Telephone	(619) 784-2937	Fax	(619) 784-9399

Name (Print/Type)	Thomas E. Northrup	Registration No. (Attorney/Agent)	33,268
Signature	Thomas E. Northrup	Date	3/26/99

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

FIRST AVAILABLE COPY

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

I HEREBY DECLARE THAT:

My residence, post office address, and citizenship are as stated next to my name in PART A of page 2 hereof.

I believe I am the original, first, and sole inventor (if only one name is listed) or an original, first, and joint inventor (if plural names are listed) of the subject matter which is claimed and for which a patent is sought on the invention entitled IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T CELLS, the specification of which:

       is attached hereto  
X was filed on December 14, 1995, as Application Serial No. PCT/US95/16415  
and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Sec. 1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, Sec. 119 of any foreign application(s) for patent or inventor's certificate listed in PART B on page 2 hereof and have also identified in PART B on page 2 hereof any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

I hereby claim the benefit under Title 35, United States Code, Sec. 120 of any United States application(s) listed in PART C on page 2 hereof and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, Sec. 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, Sec. 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following as my attorneys or agents with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

Douglas A. Bingham	Reg. No. 32,457	Donald G. Lewis	Reg. No. 28,636
Thomas Fitting	Reg. No. 34,163	Emily Holmes	Reg. No. P-40,652

whose mailing address for this application is:

THE SCRIPPS RESEARCH INSTITUTE  
10550 North Torrey Pines Road  
Mail Drop TPC 8  
La Jolla, California 92037

See Page 2 attached, signed, and made a part hereof.


BEST AVAILABLE COPY

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY

PART A: Inventor Information And Signature

Full name of SOLE or FIRST inventor Linda A. Sherman  
Citizenship US Post Office Address 7766 Hillside Drive  
La Jolla, California 92037

Residence (if different) \_\_\_\_\_

Inventor's Signature:  Date: Aug 5, 1997

Full name of SECOND joint inventor, if any \_\_\_\_\_

Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_

Residence (if different) \_\_\_\_\_

Second Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of THIRD joint inventor, if any \_\_\_\_\_

Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_

Residence (if different) \_\_\_\_\_

Third Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FOURTH joint inventor, if any \_\_\_\_\_

Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_

Residence (if different) \_\_\_\_\_

Fourth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Full name of FIFTH joint inventor, if any \_\_\_\_\_

Citizenship \_\_\_\_\_ Post Office Address \_\_\_\_\_

Residence (if different) \_\_\_\_\_

Fifth Inventor's Signature: \_\_\_\_\_ Date: \_\_\_\_\_

PART B: Prior Foreign Application(s)

Serial No.	Country	Day/Month/Year Filed	Priority Claimed
			<input type="checkbox"/> Yes <input type="checkbox"/> No

PART C: Claim For Benefit of Filing Date of Earlier U.S. Application(s)

Serial No.	Filing Date	Status:	
08/355,558	December 14, 1994	<input type="checkbox"/> Patented <input checked="" type="checkbox"/> Pending <input type="checkbox"/> Abandoned	
		<input type="checkbox"/> Patented <input type="checkbox"/> Pending <input type="checkbox"/> Abandoned	

See Page 1 to which this is attached and from which this Page 2 continues.

Certification under 37 CFR 1.10 (if applicable)

EM601456549US

"Express Mail" mailing label number


June 13, 1997

Date of deposit

I hereby certify that this Transmittal letter, enclosed application, and any other documents referred to as enclosed herein are being deposited in an envelope with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Lori A. Linderman

(Typed name of person mailing application)

  
(Signature of person mailing application)

**TRANSMITTAL LETTER TO THE UNITED STATES  
DESIGNATED/ELECTED OFFICE (DO/EO/US)**

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE(S) CLAIMED

PCT/US95/16415

14 December 1995

14 December 1994

TITLE OF INVENTION

IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T CELLS

APPLICANT(S) FOR DO/EO/US

Linda A. Sherman

Applicants herewith submit to the United States Designated/Elected Office (DO/EO/US) the following items under 35 U.S.C. 371:

1. This express request to immediately begin national examination procedures (35 U.S.C. 371(f)).
2. The U.S. National Fee (35 U.S.C. 371(c)(1)) and other fees are calculated based on the claims as filed.

FOR	NUMBER FILED	NUMBER EXTRA	RATE	CALCULATIONS
TOTAL CLAIMS	60 - 20	40	X \$ 22.00	\$ 880.00
INDEPENDENT CLAIMS	19 - 3	16	X \$ 80.00	1,280.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	0.00
BASIC NATIONAL FEE (37 CFR 1.492(A)(1)-(4)) where an international preliminary examination fee was paid to USPTO.....			\$770.00	770.00
				= \$2,930.00
TOTAL OF ABOVE CALCULATIONS				

Reduction by 1/2 for filing by small entity, if applicable. Affidavit must be filed also (Note 37 CFR 1.9, 1.27, 1.28.) .....\$ _____	0.00
TOTAL FEES ENCLOSED	\$ 2,930.00

3. Check No. 1828 in the amount of \$2,930.00 to cover the above fees is enclosed.
4. The Commissioner is hereby authorized to charge any additional fees which may be required in this application or at any time to maintain pendency of this application, or credit any overpayment to Deposit Account No. 19-0962. A duplicate copy of this sheet is enclosed.
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is not required, as the application was filed in the United States Receiving Office (RO/US).

6. An oath or declaration of the inventors (unsigned) (35 U.S.C. 371(c)(4)).
7. The above items are being transmitted by 30 months and a proper demand for International Preliminary Examination was made by the 19 month from the earliest claimed priority.
8. At the time of transmittal, amendment to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) have not been made and will not be made.

Date: June 13, 1997 Attorney's Signature Thomas Fitting

Name and Reg. No. Thomas Fitting,  
Reg. No. 34,163

Correspondence Address:

THE SCRIPPS RESEARCH INSTITUTE  
Office of Patent Counsel  
10550 North Torrey Pines Road  
Mail Drop TPC-8  
La Jolla, California 92037  
(619) 784-2937

LLC:\WP\PTO\SCR\_\_\_\_\_P.USA

PCT

REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

For receiving Office use only

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum)

TSRI433.1PC

Box No. I TITLE OF INVENTION

IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T-CELLS

Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

THE SCRIPPS RESEARCH INSTITUTE  
10666 North Torrey Pines Road  
La Jolla, California 92037  
United States of America

This person is also inventor.

Telephone No.

(619) 554-2937

Faxsimile No.

(619) 554-6312

Teleprinter No.

State (i.e. country) of nationality:

US

State (i.e. country) of residence:

US

This person is applicant  all designated States  all designated States except the United States of America  the United States of America only  the States indicated in the Supplemental Box for the purposes of:

Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

SHERMAN, Linda A.  
7766 Hillside Drive  
La Jolla, California 92037

This person is:

applicant only

applicant and inventor

inventor only (If this check-box is marked, do not fill in below.)

State (i.e. country) of nationality:

US

State (i.e. country) of residence:

US

This person is applicant  all designated States  all designated States except the United States of America  the United States of America only  the States indicated in the Supplemental Box for the purposes of:

Further applicants and/or (further) inventors are indicated on a continuation sheet.

Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:

agent  common representative

Telephone No.

(619) 554-2937

Faxsimile No.

(619) 554-6312

Teleprinter No.

April C. Logan  
The Scripps Research Institute  
10666 North Torrey Pines Road, TPC-8  
La Jolla, California 92037  
United States of America

BEST AVAILABLE COPY

## Box No.V DESIGNATION OF STATES

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

## Regional Patent

AP ARIPO Patent: KE Kenya, MW Malawi, SD Sudan, SZ Swaziland, UG Uganda and any other State which is a Contracting State of the Harare Protocol and of the PCT

EP European Patent: AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, DE Germany, DK Denmark, ES Spain, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT

OA OAPI Patent: BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

## National Patent (if other kind of protection or treatment desired, specify on dotted line):

<input checked="" type="checkbox"/> AM Armenia .....	<input checked="" type="checkbox"/> MD Republic of Moldova .....
<input checked="" type="checkbox"/> AT Austria .....	<input checked="" type="checkbox"/> MG Madagascar .....
<input checked="" type="checkbox"/> AU Australia .....	<input checked="" type="checkbox"/> MN Mongolia .....
<input checked="" type="checkbox"/> BB Barbados .....	<input checked="" type="checkbox"/> MW Malawi .....
<input checked="" type="checkbox"/> BG Bulgaria .....	<input checked="" type="checkbox"/> MX Mexico .....
<input checked="" type="checkbox"/> BR Brazil .....	<input checked="" type="checkbox"/> NO Norway .....
<input checked="" type="checkbox"/> BY Belarus .....	<input checked="" type="checkbox"/> NZ New Zealand .....
<input checked="" type="checkbox"/> CA Canada .....	<input checked="" type="checkbox"/> PL Poland .....
<input checked="" type="checkbox"/> CH and LI Switzerland and Liechtenstein .....	<input checked="" type="checkbox"/> PT Portugal .....
<input checked="" type="checkbox"/> CN China .....	<input checked="" type="checkbox"/> RO Romania .....
<input checked="" type="checkbox"/> CZ Czech Republic .....	<input checked="" type="checkbox"/> RU Russian Federation .....
<input checked="" type="checkbox"/> DE Germany .....	<input checked="" type="checkbox"/> SD Sudan .....
<input checked="" type="checkbox"/> DK Denmark .....	<input checked="" type="checkbox"/> SE Sweden .....
<input checked="" type="checkbox"/> EE Estonia .....	<input checked="" type="checkbox"/> SG Singapore .....
<input checked="" type="checkbox"/> ES Spain .....	<input checked="" type="checkbox"/> SI Slovenia .....
<input checked="" type="checkbox"/> FI Finland .....	<input checked="" type="checkbox"/> SK Slovakia .....
<input checked="" type="checkbox"/> GB United Kingdom .....	<input checked="" type="checkbox"/> TJ Tajikistan .....
<input checked="" type="checkbox"/> GE Georgia .....	<input checked="" type="checkbox"/> TM Turkmenistan .....
<input checked="" type="checkbox"/> HU Hungary .....	<input checked="" type="checkbox"/> TT Trinidad and Tobago .....
<input checked="" type="checkbox"/> IS Iceland .....	<input checked="" type="checkbox"/> UA Ukraine .....
<input checked="" type="checkbox"/> JP Japan .....	<input checked="" type="checkbox"/> UG Uganda .....
<input checked="" type="checkbox"/> KE Kenya .....	<input checked="" type="checkbox"/> US United States of America .....
<input checked="" type="checkbox"/> KG Kyrgyzstan .....	Continuation-in-part application .....
<input checked="" type="checkbox"/> KP Democratic People's Republic of Korea .....	
<input checked="" type="checkbox"/> KR Republic of Korea .....	
<input checked="" type="checkbox"/> KZ Kazakhstan .....	
<input checked="" type="checkbox"/> LK Sri Lanka .....	
<input checked="" type="checkbox"/> LR Liberia .....	
<input checked="" type="checkbox"/> LT Lithuania .....	
<input checked="" type="checkbox"/> LU Luxembourg .....	
<input checked="" type="checkbox"/> LV Latvia .....	

Check-boxes reserved for designating States (for the purposes of a national patent) which have become party to the PCT after issuance of this sheet:

.....

.....

.....

.....

In addition to the designations made above, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except the designation(s) of \_\_\_\_\_.

The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation of a designation consists of the filing of a notice specifying that designation and the payment of the designation and confirmation

**Supplemental Box**      If the Supplemental Box is not used, this sheet need not be included in the request.

**Use this box in the following cases:**

**1. If, in any of the Boxes, the space is insufficient to furnish all the information:**

in particular:

- (i) if more than two persons are involved as applicants and/or inventors and no "continuation sheet" is available;
- (ii) if, in Box No. II or in any of the sub-boxes of Box No. III, the indication "the States indicated in the Supplemental Box" is checked;
- (iii) if, in Box No. II or in any of the sub-boxes of Box No. III, the inventor or the inventor/applicant is not inventor for the purposes of all designated States or for the purposes of the United States of America;
- (iv) if, in addition to the agent(s) indicated in Box No. IV, there are further agents;
- (v) if, in Box No. V, the name of any State (or OAPI) is accompanied by the indication "parent of addition," or "certificate of addition," or if, in Box No. V, the name of the United States of America is accompanied by an indication "Continuation" or "Continuation-in-part";
- (vi) if there are more than three earlier applications whose priority is claimed;

**2. If the applicant claims, in respect of any designated Office, the benefits of provisions of the national law concerning non-prejudicial disclosures or exceptions to lack of novelty:**

in such case, write "Continuation of Box No. ..." [indicate the number of the Box] and furnish the information in the same manner as required according to the captions of the Box in which the space was insufficient;

in such case, write "Continuation of Box No. III" and indicate for each additional person the same type of information as required in Box No. III;

in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the applicant(s) involved and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, European or OAPI patent) for the purposes of which the named person is applicant;

in such case, write "Continuation of Box No. II" or "Continuation of Box No. III" or "Continuation of Boxes No. II and No. III" (as the case may be), indicate the name of the inventor(s) and, next to (each) such name, the State(s) (and/or, where applicable, ARIPO, European or OAPI patent) for the purposes of which the named person is inventor;

in such case, write "Continuation of Box No. IV" and indicate for each further agent the same type of information as required in Box No. IV;

in such case, write "Continuation of Box No. V" and the name of each State involved (or OAPI), and after the name of each such State (or OAPI), the number of the parent title or parent application and the date of grant of the parent title or filing of the parent application;

in such case, write "Continuation of Box No. VI" and indicate for each additional earlier application the same type of information as required in Box No. VI.

in such case, write "Statement Concerning Non-Prejudicial Disclosures or Exceptions to Lack of Novelty" and furnish that statement below.

**Continuation of Box IV**


Douglas A. Bingham  
 Thomas Fitting  
 Donald G. Lewis  
 The Scripps Research Institute  
 10666 North Torrey Pines Road, TPC-8  
 La Jolla, California 92037  
 United States of America

**Continuation of Box V**

U.S. Serial No. 08/355,558, filed 14.12.94

**Sequence Listing Declaration**

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(a) through (c) and (e), and in accordance with the EPO Rules OJ 12/1992, respectively, are the same.

  
 April C. Logan, Agent

**Box No. VI PRIORITY CLAIM.**Further priority claims are indicated in the Supplemental Box 

The priority of the following earlier application(s) is hereby claimed:

Country (in which, or for which, the application was filed)	Filing Date (day/month/year)	Application No.	Office of filing (only for regional or international application)
item (1) US	14.12.94 14 December 1994	08/355,558	
item (2)			
item (3)			

Mark the following check-box if the certified copy of the earlier application is to be issued by the Office which for the purposes of the present international application is the receiving Office (a fee may be required):

The receiving Office is hereby requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) identified above as item(s): (1)

**Box No. VII INTERNATIONAL SEARCHING AUTHORITY**

Choice of International Searching Authority (ISA) (If two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used): ISA / US

Earlier search Fill in where a search (international, international-type or other) by the International Searching Authority has already been carried out or requested and the Authority is now requested to base the international search, to the extent possible, on the results of that earlier search. Identify such search or request either by reference to the relevant application (or the translation thereof) or by reference to the search request:

Country (or regional Office): Date (day/month/year): Number:

**Box No. VIII CHECK LIST**

This international application contains the following number of sheets:

- 1. request : 4 sheets
- 2. description : 123 sheets
- 3. claims : 7 sheets
- 4. abstract : 1 sheets
- 5. drawings : 19 sheets

Total : 154 sheets


This international application is accompanied by the item(s) marked below:

- 1.  separate signed power of attorney
- 2.  copy of general power of attorney
- 3.  statement explaining lack of signature
- 4.  priority document(s) identified in Box No. VI as item(s):
- 5.  fee calculation sheet
- 6.  separate indications concerning deposited microorganisms
- 7.  nucleotide and/or amino acid sequence listing (diskette)
- 8.  other (specify): Transmittal Letter

Figure No. \_\_\_\_\_ of the drawings (if any) should accompany the abstract when it is published.

**Box No. IX SIGNATURE OF APPLICANT OR AGENT**

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).

  
April C. Logan  
Agent

## For receiving Office use only

1. Date of actual receipt of the purported international application:
3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application:
4. Date of timely receipt of the required corrections under PCT Article 11(2):

5. International Searching Authority specified by the applicant: ISA /

6.  Transmittal of search copy delayed until search fee is paid

## 2. Drawings:

received:

not received:

## For International Bureau use only

Date of receipt of the record copy

PCT AVAILABLE COPY

433.1 PC  
SCR1773P**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/02, 38/08, 38/10, 38/16, C12N 5/16, C07K 7/00, G01N 33/53</b>		A1	(11) International Publication Number: <b>WO 96/18409</b>
			(43) International Publication Date: 20 June 1996 (20.06.96)
(21) International Application Number: PCT/US95/16415		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG).	
(22) International Filing Date: 14 December 1995 (14.12.95)			
(30) Priority Data: X 08/355,558 14 December 1994 (14.12.94) US			
(60) Parent Application or Grant		Published	
(63) Related by Continuation US 08/355,558 (CIP) Filed on 14 December 1994 (14.12.94)		With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(71) Applicant (for all designated States except US): THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10666 North Torrey Pines Road, La Jolla, CA 92037 (US).			
(72) Inventor; and			
(75) Inventor/Applicant (for US only): SHERMAN, Linda, A. [US/US]; 7766 Hillside Drive, La Jolla, CA 92037 (US).			
(74) Agents: LOGAN, April, C. et al.; The Scripps Research Institute, 10666 North Torrey Pines Road, TPC-8, La Jolla, CA 92037 (US).			

(54) Title: IN VIVO ACTIVATION OF TUMOR-SPECIFIC CYTOTOXIC T CELLS

## (57) Abstract

The present invention relates to methods, compositions, and peptides useful in activating CTLs *in vivo* with specificity for particular antigenic peptides. The invention also discloses the use of activated CTLs *in vivo* for the diagnosis and treatment of a variety of disease conditions, and compositions appropriate for these uses. Diagnostic systems, components, and methods are also described herein.